Mission Statement, Vision, & Core Values (2026) of BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd. combines a patient-centric mission to reduce the burden of infectious and autoimmune diseases with a clear vision to become a leader in innovative immunotherapies, leveraging a proven clinical pedigree that includes a Phase 3 trial enrolling 12,400 participants across seven countries and a research and production hub housed in a state-of-the-art GMP facility in Jerusalem; founded in 2003 and led since 2021 by CEO Amir Reichman, the company has pivoted from its influenza vaccine work toward a diversified pipeline of nanosized antibody (NanoAb) therapeutics-targeting conditions such as COVID-19, asthma, and psoriasis-through strategic collaborations with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, all while remaining publicly traded as NASDAQ: BVXV $0.8821, reflecting market valuation as it scales innovation, integrity, collaboration, patient-centricity, and sustainability across R&D, manufacturing, and commercialization.

BiondVax Pharmaceuticals Ltd. (BVXV) - Intro

• Founded: 2003 (Israel)
• Primary focus: Immunotherapeutics for infectious and autoimmune diseases
• Strategic pivot: NanoAb therapeutics platform (collaborations with Max Planck Institute and University Medical Center Göttingen)
• Leadership: CEO Amir Reichman (appointed 2021)
• NASDAQ ticker: BVXV - trading at $0.8821 as of December 16, 2025

• Patient-centric outcomes: prioritize therapies that reduce morbidity/mortality across populations
• Platform-driven value: leverage NanoAb technology to create modular, rapid-to-deploy therapeutics
• Manufacturing integrity: maintain GMP operations to ensure reproducible quality and supply continuity

• Global reach: move beyond single-country programs to multinational development and commercialization
• Platform scalability: expand NanoAb applications across multiple indications and delivery formats
• Investor alignment: deliver sustained value through disciplined development, partnerships, and manufacturing leverage

• Scientific rigor - evidence-based development guided by robust clinical data (historically including a Phase 3 influenza trial with 12,400 participants across seven countries)
• Quality & compliance - adherence to GMP and regulatory standards in manufacturing and clinical conduct
• Collaboration - strategic partnerships with leading academic institutions to accelerate innovation
• Transparency - timely disclosure to investors, partners, and regulators
• Patient access - focus on scalable solutions that can be manufactured and distributed broadly

• Advance NanoAb pipeline through preclinical proof-of-concept and IND-enabling studies
• Leverage GMP facility to support early commercial manufacturing and partner supply needs
• Pursue partnerships and licensing to de-risk development and accelerate market access
• Maintain financial discipline while communicating milestones to investors

BiondVax Pharmaceuticals Ltd. (BVXV) - Overview

• BiondVax Pharmaceuticals Ltd. (BVXV) is dedicated to developing and commercializing innovative vaccines and immunotherapies that enhance patient health worldwide.
• The company focuses on reducing the burden of infectious diseases by leveraging an advanced technology platform to create effective treatments, with a strategic shift toward nanosized antibody (NanoAb) therapeutics to address unmet medical needs.
• BVXV emphasizes a patient-centric approach, prioritizing improved clinical outcomes, broader access, and portfolios that mitigate risk via diversification across vaccine and therapeutic platforms.
• Collaboration-driven R&D with leading academic and industry partners underpins the mission, advancing healthcare through cutting-edge science and translational research.

• Transition from traditional vaccine programs to a pipeline centered on NanoAb therapeutics for infectious disease and potentially oncology indications.
• Risk mitigation through platform diversification: multi-modal approaches including recombinant proteins, adjuvant systems, and NanoAb constructs.
• Commercialization readiness: target partnerships and licensing to accelerate scale-up and market entry while preserving upside via retained rights or royalties.

• Science-driven R&D: allocation of the majority of internal resources toward platform innovation and NanoAb lead optimization.
• Collaborative network: strategic alliances with academic institutions and CROs to accelerate preclinical development and IND-enabling studies.
• Portfolio diversification: balancing vaccine heritage with novel therapeutic modalities to spread development risk and open multiple commercial pathways.

• Primary aim: reduce morbidity and mortality from infectious diseases through both preventative vaccines and therapeutic antibodies.
• Global health considerations: program designs that target scalable manufacturing and broad geographic applicability to improve access in diverse markets.
• Measured outcomes: clinical endpoints and health-economic assessments are prioritized in program design to demonstrate real-world benefit and payer value.

BiondVax Pharmaceuticals Ltd. (BVXV) - Mission Statement

• Advancing a diversified pipeline that integrates proprietary NanoAb therapeutics alongside vaccine and biologic platforms.
• Translating preclinical and early clinical successes into commercial-stage products targeting high-unmet-need indications such as COVID-19, asthma and psoriasis.
• Leveraging strategic scientific collaborations to accelerate discovery and product development.
• Utilizing internal GMP manufacturing capabilities to enable rapid scale-up, tech transfer, and cost-efficient commercialization.
• Delivering measurable public health impact through therapies designed for broad access and scalable manufacturing.

• Access to advanced structural biology and single-domain antibody engineering expertise.
• Joint preclinical programs that shorten lead identification timelines.
• Shared translational pathways for moving NanoAb candidates toward IND-enabling studies.

• GMP Manufacturing: BVXV has invested in an internal GMP manufacturing facility to support both clinical supply and early commercial needs, aiming to shorten timelines for first-in-human to pivotal studies.
• R&D Investment: The company prioritizes reinvestment into NanoAb discovery, preclinical development and manufacturing scale-up to support multiple IND-enabling programs.
• Capital and Runway: As BVXV advances preclinical candidates toward clinical stages, funding strategy focuses on partnering, non-dilutive grants, and targeted equity or licensing transactions to extend runway for key value inflection points.

• Platform Differentiation: NanoAbs offer potential advantages in tissue penetration, stability and rapid manufacturability versus conventional mAbs.
• Go-to-Market Strategy: Sequential indication prioritization-targeting acute unmet needs with clear regulatory pathways (e.g., respiratory viral therapeutics)-before expansion into chronic inflammatory conditions.
• Partnership Model: Strategic partnerships for late-stage development, regulatory filings and commercialization to maximize reach while conserving capital.

BiondVax Pharmaceuticals Ltd. (BVXV) - Vision Statement

• Innovation - BiondVax places innovation at the center of its R&D model, investing in next-generation immunotherapies and vaccine platforms designed to achieve broad and durable protection against evolving pathogens.
• Integrity - Ethical conduct governs clinical development, regulatory interactions, and corporate governance, promoting transparency and trust among patients, partners, regulators, and investors.
• Collaboration - Strategic partnerships with academic institutions, contract research organizations, manufacturing partners, and global public health stakeholders expand scientific capabilities and accelerate development timelines.
• Patient-Centricity - Product design and clinical strategy prioritize patient needs, emphasizing safety, accessibility, and clinically meaningful endpoints that improve patient outcomes.
• Sustainability - Environmental responsibility is integrated into R&D and manufacturing planning to minimize resource use, reduce waste, and support long-term operational resilience.

• Innovation: Allocating resources to iterative antigen design and diversified platform approaches to mitigate single-strain failure risk.
• Integrity: Maintaining rigorous clinical trial governance, publishing peer-reviewed results, and adhering to global regulatory standards.
• Collaboration: Structuring co-development and licensing agreements to leverage external expertise and scale manufacturing rapidly when needed.
• Patient-Centricity: Designing trials with patient-reported outcomes, safety-first dosing strategies, and access strategies for low- and middle-income countries.
• Sustainability: Incorporating energy- and resource-efficient manufacturing practices and waste-reduction targets into partner contracts.

• Governance: Board and management accountability to maintain ethical compliance, clear disclosure practices, and investor communication cadence.
• Financial Stewardship: Prioritizing capital allocation to clinical milestones, with disciplined burn-rate management and contingency planning.
• Transparent Reporting: Regular updates aligned to clinical readouts, regulatory interactions, and material partnership developments to retain stakeholder confidence.